VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

APC8015F

Vaccine Information

Vaccine Name: APC8015F
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007271
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
ACPP gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Prostate-specific membrane antigen gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
KLK3 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Adjuvant:
- Adjuvant name:
- VO adjuvant ID: VO_0001294
Preparation: Autologous dendritic cells were pulsed ex vivo with PA2024, a recombinant fusion protein consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase (Harzstark and Small, 2007).
Description: A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCIT_C48640).

This vaccine has been used in trials involving asymptomatic, metastatic, hormone-refractory prostate cancer. (Small et al., 2014; Ju et al., 2022)

Host Response

References

Harzstark and Small, 2007: Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert opinion on biological therapy. 2007; 7(8); 1275-1280. [PubMed: 17696825].

Ju et al., 2022: Ju M, Fan J, Zou Y, Yu M, Jiang L, Wei Q, Bi J, Hu B, Guan Q, Song X, Dong M, Wang L, Yu L, Wang Y, Kang H, Xin W, Zhao L. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer. Frontiers in immunology. 2022; 13; 807840. [PubMed: 35812443].

NCIT_C48640: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48640]

Small et al., 2014: Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate cancer and prostatic diseases. 2014; 17(3); 259-264. [PubMed: 24957547].